Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARA 290 intravenous study in end-stage renal disease patients
NL-OMON33202Phase 2Active, not recruiting
- Sponsor
- Araim Pharmaceuticals, Inc
- Start
- Jan 2010
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in end-stage kidney disease (ESKD) comparing ARA 290 with Placebo (2 arms). Primary endpoints: Safety and tolerability, Pharmacokinetics of ARA 290 and 1 more. Started Jan 2010; status: active, not recruiting.
02
Drugs
cibinetide
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NL-OMON33202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33202.